Skip to content

The effects of on the rheologic properties and oxygen transport capacity of red blood cells processed by 3 different types of cell savers, and its effects on microcirculatory blood flow and tissue oxygenation in vivo

The effects of on the rheologic properties and oxygen transport capacity of red blood cells processed by 3 different types of cell savers, and its effects on microcirculatory blood flow and tissue oxygenation in vivo - Cell savers and blood quality

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON40462
Enrollment
200
Registered
2013-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood quality cell saver

Interventions

randomized to one of the three cellsavers

Sponsors

anesthesiologie- onderzoeksbureau
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: Scheduled for OPCABG age>18 year

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Patients with known hematologic or microvascular disorders. Patients will be excluded intraoperatively when conversion to on-pump coronary artery bypass grafting is necessary or when allogeneic red blood cell transfusion is required

Design outcomes

Primary

MeasureTime frame
Primary endpoint of this study is the quality of the washed red blood cells, measured by their deformability and oxygen carrying capacity

Secondary

MeasureTime frame
the effects of retransfusion of washed cell saver blood in the patient measured by microcirculatory blood flow and tissue oxygenation, and by biochemical markers of organ damage.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)